Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma

BACKGROUND: The purpose of the study was to assess the efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) who are undergoing hepatic arterial infusion chemotherapy (HAIC) combined with programmed cell death protein-1 (PD-1) antibody and lenvatinib. METHODS: We retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yongkang, Fu, Shumin, Mao, Ye, Huang, Shenglan, Li, Dan, Wu, Jianbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474651/
https://www.ncbi.nlm.nih.gov/pubmed/36117969
http://dx.doi.org/10.3389/fmed.2022.919069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474651/
https://www.ncbi.nlm.nih.gov/pubmed/36117969
http://dx.doi.org/10.3389/fmed.2022.919069

Ejemplares similares